Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Navicare Biotech CoROCO:8472 -3.07%53 Current Ratio is 0.68 as of Dec. 2025, which is 56% below its 10-year median of 1.53. GuruFocus rates ROCO:8472 with a GF Score™ of 53/100 and a GF Value™ of NT$44.21 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 1,128 Retail - Cyclical companies, Navicare Biotech Co ranks worse than 89.89% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Navicare Biotech Co's current ratio for the quarter that ended in Dec. 2025 was 0.68.
Navicare Biotech Co has a current ratio of 0.68. It indicates that the company may have difficulty meeting its current obligations. Low values, however, do not indicate a critical problem. If Navicare Biotech Co has good long-term prospects, it may be able to borrow against those prospects to meet current obligations.
The historical rank and industry rank for Navicare Biotech Co's Current Ratio or its related term are showing as below:
ROCO:8472'
s Current Ratio Range Over the Past 10 Years
Min: 0.42 Med: 1.53 Max: 1.6
Current: 0.68
During the past 13 years, Navicare Biotech Co's highest Current Ratio was 1.60. The lowest was 0.42. And the median was 1.53.
ROCO:8472's Current Ratio is ranked worse than 89.89% of 1128
companies
in the Retail - Cyclical industry
Industry Median: 1.58
vs ROCO:8472: 0.68
Navicare Biotech Co (ROCO:8472) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Navicare Biotech Co Current Ratio Related Terms
Navicare Biotech Co Current Ratio Historical Data
* Premium members only.
The historical data trend for Navicare Biotech Co's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:8472 vs AMZN, BABA, PDD: Current Ratio Comparison
For the Internet Retail subindustry, Navicare Biotech Co's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Navicare Biotech Co Current Ratio vs Retail - Cyclical Industry
For the Retail - Cyclical industry and Consumer Cyclical sector, Navicare Biotech Co's Current Ratio distribution charts can be found below:
* The bar in red indicates where Navicare Biotech Co's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Navicare Biotech Co (ROCO:8472) has a Current Ratio of 0.68 as of Dec. 2025. This is 56% below median its historical median of 1.53. Over the past decade, Navicare Biotech Co's Current Ratio has ranged from 0.42 to 1.60. According to the industry distribution chart, Navicare Biotech Co ranks #1014 out of 1128 companies in the Retail - Cyclical industry, placing it in the top 89.9%.
Is Navicare Biotech Co's Current Ratio too high?
Navicare Biotech Co's current Current Ratio of 0.68 is 56% below median its 10-year median of 1.53. Over the past 10 years, this metric has ranged from a low of 0.42 to a high of 1.60. The Retail - Cyclical industry median Current Ratio is 1.58. Navicare Biotech Co's value of 0.68 is 57% below this industry median. Based on the distribution chart, Navicare Biotech Co ranks #1014 out of 1128 companies in the Retail - Cyclical industry, which is in the bottom quartile relative to peers. Overall, Navicare Biotech Co has a GF Score™ of 53/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Navicare Biotech Co's Current Ratio compare to AMZN and BABA?
According to the Retail - Cyclical industry distribution chart, Navicare Biotech Co ranks #1014 out of 1128 companies for Current Ratio. This places Navicare Biotech Co in the lower half of its industry. The industry median Current Ratio is 1.58. Navicare Biotech Co's value of 0.68 is 57% below this benchmark. Historically, Navicare Biotech Co's own Current Ratio has ranged from 0.42 to 1.60 over the past decade. While the company's 10-year median is 1.53 vs. the industry median of 1.58, Navicare Biotech Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Retail - Cyclical company?
The median Current Ratio among Retail - Cyclical companies is 1.58, based on 1,128 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Navicare Biotech Co's current Current Ratio of 0.68 is 57% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Retail - Cyclical industry, the median Current Ratio is 1.58 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Navicare Biotech Co's current Current Ratio is 0.68, which is 56% below median its own 10-year median of 1.53. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Navicare Biotech Co stock overvalued right now?
Based on GuruFocus' analysis, Navicare Biotech Co (ROCO:8472) is currently considered Significantly Overvalued. The stock's GF Value™ is NT$44.21, compared to a current price of NT$79.00 — trading 78.7% above its estimated fair value. The current Current Ratio is 0.68, which is 56% below median its 10-year median of 1.53 and 57% below the Retail - Cyclical industry median of 1.58. Navicare Biotech Co's overall GF Score™ is 53/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Navicare Biotech Co (ROCO:8472), the current Current Ratio is 0.68 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Navicare Biotech Co (ROCO:8472) Overvalued in 2026?
Based on GuruFocus' analysis, Navicare Biotech Co stock appears to be overvalued.
The current stock price of NT$79.00 is trading 78.7% above its estimated GF Value™ of NT$44.21.
GuruFocus considers Navicare Biotech Co to be Significantly Overvalued.
Key valuation signals for ROCO:8472:
Current Ratio: 0.68 (56% below median its 10-year median of 1.53)
GF Value™: NT$44.21 vs. price of NT$79.00 (78.7% above fair value)
Industry Position: 57% below the Retail - Cyclical median (#1014 of 1128)
No single metric tells the full story. See the ROCO:8472 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:8472 has been successfully added to your 
